Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/10971
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZoeller, RT-
dc.contributor.authorBergman, A-
dc.contributor.authorBecher, G-
dc.contributor.authorBjerregaard, P-
dc.contributor.authorBornman, R-
dc.contributor.authorBrandt, I-
dc.contributor.authorIguchi, T-
dc.contributor.authorJobling, S-
dc.contributor.authorKidd, KA-
dc.contributor.authorKortenkamp, A-
dc.contributor.authorSkakkebaek, NE-
dc.contributor.authorToppari, J-
dc.contributor.authorVandenberg, LN-
dc.date.accessioned2015-06-05T13:56:49Z-
dc.date.available2014-12-22-
dc.date.available2015-06-05T13:56:49Z-
dc.date.issued2014-
dc.identifier.citationEnvironmental Health, 13: 118, (December 2014)en_US
dc.identifier.issn1476-069X-
dc.identifier.urihttp://www.ehjournal.net/content/13/1/118/abstract-
dc.identifier.urihttp://bura.brunel.ac.uk/handle/2438/10971-
dc.description.abstractSeveral recent publications reflect debate on the issue of “endocrine disrupting chemicals” (EDCs), indicating that two seemingly mutually exclusive perspectives are being articulated separately and independently. Considering this, a group of scientists with expertise in basic science, medicine and risk assessment reviewed the various aspects of the debate to identify the most significant areas of dispute and to propose a path forward. We identified four areas of debate. The first is about the definitions for terms such as “endocrine disrupting chemical”, “adverse effects”, and “endocrine system”. The second is focused on elements of hormone action including “potency”, “endpoints”, “timing”, “dose” and “thresholds”. The third addresses the information needed to establish sufficient evidence of harm. Finally, the fourth focuses on the need to develop and the characteristics of transparent, systematic methods to review the EDC literature. Herein we identify areas of general consensus and propose resolutions for these four areas that would allow the field to move beyond the current and, in our opinion, ineffective debate.en_US
dc.description.sponsorshipThe authors gratefully acknowledge the following agencies: Swedish governmental academic research through Research Council, Stockholm University, Karolinska Institute, Stockholm County Council, Knut and Alic Wallenberg Foundation (alb); The Research Council Formas, and the Swedish Foundation for Strategic Environmental Research (Mistra) through the MistraPharma research program (ib), The Danish Innovation fund (nek); European Commission DG Environment, the European Food Safety Authority, DG Research (FP7 Quality of Life), the Danish EPA, the French ANSES, the OAK Foundation Geneva (ak); National Research Fund, the Medical Research Council and the University of Pretoria (rb); Academy of Finland and Sigrid Juselius Foundation, EU Fp7 Quality of Life, and Turku University Hospital (jt); National Institutes of Environmental Health Science (rtz).en_US
dc.format.extent? - ? (11)-
dc.languageEnglish-
dc.language.isoenen_US
dc.publisherBioMed Central Ltden_US
dc.subjectEndocrine disruptoren_US
dc.subjectUNEPen_US
dc.subjectWHOen_US
dc.subjectState of the scienceen_US
dc.titleA path forward in the debate over health impacts of endocrine disrupting chemicalsen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1186/1476-069X-13-118-
dc.relation.isPartOfENVIRONMENTAL HEALTH-
pubs.publication-statusPublished-
pubs.publication-statusPublished-
pubs.volume13-
pubs.volume13-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
Fulltext.pdf207.52 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.